Global EPA/DHA Market - Forecast(2023 - 2028)

Global EPA/DHA Market size is estimated to reach $4.4 billion by 2027, growing at a CAGR of 7.1% during the forecast period 2022-2027. EPA and DHA stand for eicosapentaenoic acid and docosahexaenoic acid correspondingly. These fatty acids are omega-3 fats, which are discovered in cold water fish. EPA and DHA are greatly unsaturated fats owing to the inclusion of six and five double bonds on their long structural chains. A greater proportion of Eicosapentaenoic Acid (EPA) when mixed with docosahexaenoic acid (DHA) in Omega-3 dietary supplements offer greater antioxidant impacts in human retinal cells. Epidemiological and genetic investigations recommend that increased triglycerides (TGs)-rich lipoprotein levels in the circulation raise the hazard of cardiovascular disease. Prescription formulations of omega-3 fatty acids (OM3FAs), principally, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), decrease plasma TG levels and are certified for the treatment of patients with serious hypertriglyceridemia. Icosapent ethyl (Vascepa®) is a high-purity ethyl ester of eicosapentaenoic acid (EPA) that is de-esterified to EPA succeeding oral administration. Both EPA and docosahexaenoic acid (DHA) are long-chain omega-3 fatty acids that have been related to triglycerides (TG)-lowering.

The soaring application of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in food, dietary supplements, and clinical nutrition is set to drive the Global EPA/DHA Market. The surging demand for algae omega in infant food fortification owing to their advantages identical to fish oil with no off-odor or taste is set to propel the growth of the Global EPA/DHA Market during the forecast period 2022-2027. This represents the Global EPA/DHA Industry Outlook.

Report Coverage

The report: “Global EPA/DHA Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Global EPA/DHA Market.

Key Takeaways

• Geographically, Asia-Pacific Global EPA/DHA Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring production and intake consolidated of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in countries like China and Japan in the Asia-Pacific region.
• Global EPA/DHA Market growth is being driven by the surging significance and inclusion of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the everyday diet of consumers, attributed to the increased predominance of lifestyle diseases and people following preventive healthcare measures. However, it can be challenging to get the suitable consumption of EPA and DHA by way of diet only, even though EPA and DHA are generated by water plants like algae and are accepted in marine animals which is one of the major factors hampering the growth of Global EPA/DHA Market. 
• Global EPA/DHA Market Detailed Analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Global EPA/DHA Market report. 

Global EPA/DHA Market Segment Analysis – By Type:

The Global EPA/DHA Market based on type can be further segmented into Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA). The Docosahexaenoic Acid (DHA) Segment held the largest market share in 2021. This growth is owing to the surging application of docosahexaenoic acid in infant formulae and nutritional products aimed at better children's health. Docosahexaenoic acid is a key building block for the development and maturation of an infant's brain and retina. The extensive application of docosahexaenoic acid in fortified foods and dietary supplements is further propelling the growth of the Docosahexaenoic Acid (DHA) segment.

Furthermore, the Eicosapentaenoic Acid (EPA) segment is estimated to grow with the fastest CAGR of 8.6% during the forecast period 2022-2027 owing to the extensive oral administration of eicosapentaenoic acid for a few heart-related conditions like clogged heart arteries (coronary artery disease), to thwart or treat heart attacks, and to diminish levels of blood fats termed triglycerides in people with very soaring levels.

Global EPA/DHA Market Segment Analysis – By Application:

The Global EPA/DHA Market based on the application can be further segmented into Infant Formulae, Dietary Supplements, Fortified Food And Beverages, Pharmaceuticals, and Others. The Dietary Supplements Segment held the largest market share in 2021. This growth is owing to the surging application of dietary supplements including EPA and DHA (eicosapentaenoic acid and docosahexaenoic acid) omega-3 fatty acids. Eicosapentaenoic acid and docosahexaenoic acid safeguard against numerous metabolic and neurologic ailments. The proliferating application of docosahexaenoic acid for neuroinflammatory conditions and eicosapentaenoic acid for depression is further propelling the growth of this segment.

Furthermore, the Pharmaceuticals segment is estimated to grow with the fastest CAGR of 8.9% during the forecast period 2022-2027 owing to the increasing application of DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID which is an integration of two medications: Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA).

Global EPA/DHA Market Segment Analysis – By Geography:

The Global EPA/DHA Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Asia-Pacific (Global EPA/DHA Market) held the largest share with 45% of the overall market in 2021. The growth of this region is owing to the surging inclination of consumers to source omega-3 principally from fish-rich diets instead of algae-based products in the Asia-Pacific region. Eicosapentaenoic acid and docosahexaenoic acid have a critical role in brain growth and additional important functions in children. The soaring novel product innovations by key players to keep up the essential nutritional consumption of the young ones is further propelling the growth of the Global EPA/DHA Market in the Asia-Pacific region.

Furthermore, the North America region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like proliferating innovations both in products and technologies in the North American region. The trend of intake of supplements rather than functional food is dominant in the North American region. The soaring preference of consumers toward high concentrated dietary supplements to satisfy their nutritional needs of docosahexaenoic acid and eicosapentaenoic acid are further fueling the progress of the Global EPA/DHA Market in the North American region.

Global EPA/DHA Market Drivers

Surging Applications Of Eicosapentaenoic Acid Are Projected To Drive The Growth Of Global EPA/DHA Market:

Eicosapentaenoic acid is a fatty acid discovered in the flesh of cold-water fish, involving mackerel, herring, tuna, halibut, salmon, cod liver, whale blubber, or seal blubber. Eicosapentaenoic acid is consumed by mouth for certain heart-associated conditions like clogged heart arteries (coronary artery disease), to avert or treat heart attacks, and to decrease levels of blood fats termed triglycerides in people with very soaring levels. It is also applied for certain mental conditions like schizophrenia, personality disorder, Alzheimer's disease, depression, and attention deficit-hyperactivity disorder (ADHD). It is also utilized to avert loss of vision that happens in elder people (age-related macular degeneration; AMD), for psoriasis, asthma, cystic fibrosis, and diabetes. Eicosapentaenoic acid is also utilized for lung cancer, and prostate cancer, to assist in keeping up body weight in people with cancer, and to decrease the side effects of chemotherapy in people with cancer. Women utilize eicosapentaenoic acid to decrease symptoms of menopause, to decrease soaring blood pressure at the time of high-risk pregnancies, and to decrease the hazard of a baby having delayed development while still in the uterus. Clinical investigations demonstrate that an everyday dose of EPA also reduces systolic blood pressure (the top number in a blood pressure reading) by as much as 8.7%. The surging applications of eicosapentaenoic acid are therefore fuelling the growth of the Global EPA/DHA Market during the forecast period 2022-2027.

Soaring Applications Of Docosahexaenoic Acid Are Expected To Boost The Demand For EPA/DHA:

Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is discovered together with eicosapentaenoic acid (EPA) in cold-water fish, inclusive of tuna and salmon. DHA plays an essential role in the growth of eye and nerve tissues. DHA might also decrease the hazard of heart and circulatory ailment by lowering the thickness of the blood, decreasing swelling (inflammation), and lessening blood levels of triglycerides. People typically utilize DHA for soaring levels of cholesterol or additional fats in the blood. DHA can be transformed into EPA in the body in very tiny quantities. DHA has superior cardiovascular advantages. DHA is suggested to treat hypercholesterolemia, hypertriglyceridemia, and hypertension. Greater consumption of DHA is normally suggested to avert cardiovascular ailments. Owing to the soaring advancement of DHA in the retina, DHA is suggested to treat and avert age-related macular degeneration. Even X-linked retinitis pigmentosa can be enhanced with DHA supplementation. Though DHA is utilized for cognitive and mood ailments, together with EPA, it improves the result. Schizochytrium sp. is a marine thraustochytrid that combines polyunsaturated fatty acids (PUFAs) in which the priceless dietary docosahexaenoic acid (DHA, 22:6 n -3) depicts 30–40 % of the total fatty acids. The soaring applications of docosahexaenoic acid are therefore driving the growth of the Global EPA/DHA Market during the forecast period 2022-2027.

Global EPA/DHA Market Challenges

Side Effects Of DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID Are Hampering The Growth Of The Global EPA/DHA Market:

The side effects of DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID include Nausea (urge for vomiting), abdominal distension, pain, constipation, diarrhea, dyspepsia (indigestion), gas, belching, and heartburn. DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID might influence liver function. Therefore, the physician may carry out blood tests while utilizing DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID to assess liver function. The physician needs to be notified if one has had surgery or trauma currently, as DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID may raise bleeding hazards. No greater than the suggested doses need to be consumed (also dietary consumption of DHA and EPA needs to be considered) as it might result in a reduction in blood pressure, a rise in the hazard of bleeding, and a rise in blood sugar levels. Some useful figures are mentioned below:

For most the healthy individuals, normal blood sugar levels are as follows:

1. Between 4.0 to 5.4 mmol/L (72 to 99 mg/dL) when fasting
2. Up to 7.8 mmol/L (140 mg/dL) 2 hours after eating

For people with diabetes, blood sugar level targets are as follows:

1. Before meals: 4 to 7 mmol/L for people with type 1 or type 2 diabetes
2. After meals: under 9 mmol/L for people with type 1 diabetes and under 8.5mmol/L for people with type 2 diabetes

DOCOSAHEXAENOIC ACID+EICOSAPENTAENOIC ACID may interact with blood thinners (warfarin, clopidogrel, and aspirin) and stall blood clotting. These issues are thus hampering the growth of the Global EPA/DHA Market.

Global EPA/DHA Industry Outlook:

Acquisitions of tinier firms by bigger players, financing in R&D, mergers and acquisitions and partnerships are key strategies adopted by players in the Global EPA/DHA Market. Key companies in this market are:

1. Archer Daniels Midland Company
2. AlgaPrimeDHA (Corbion N.V.)
3. BASF SE
4. Koninklijke DSM NV
5. Stepan
6. Novotech Nutraceuticals
7. Nordic Naturals, Inc.
8. Epax Norway AS
9. GC Rieber
10. Biosearch Life

Recent Developments

• In December 2021, GC Rieber VivoMega, a provider of omega-3 concentrates, declared plans to persist to advance its facilities and tanks for expanded capacity of its VivoMega omega-3 for the forthcoming years. On August 8, 2010, the firm finished building its fish oil concentrate manufacturing plant in Norway. In 2013 and 2016, it finished two more extensions to its manufacturing plant to better suit market demands for greater omega-3 concentrates.
• In October 2021, GC Rieber VivoMega, a provider of soaring-quality omega-3 concentrates, declared the introduction of the VivoMega softgel sampling program. Accessible to North American consumers, the firm pronounces the samples will demonstrate how its omega-3 constituents can be utilized to aim attention at distinct health advantages. The constituent is directed to allow better taste and smell, and with omega-3 oils, there is a littlest sensory experience, inclusive of a decrease in fishy aftertaste or belches.
• In September 2020, succeeding the current extension of its omega-3 concentrate production facilities, GC Rieber Oils declared a novel line of omega-3 concentrates. The extended factory permits both a doubling of production output and including technologies to deliver the firm’s greatest EPA and DHA ratios to date. The VivoMega series, entitled Platinum, includes EPA and DHA concentrated fish oils involving up to 850 mg/g of total omega-3 content.

Related Reports

EPA and DHA Omega-3 PUFA Market - Forecast(2022 - 2027)

Report Code: FBR 0465

EPA Focused Algae Omega-3 Ingredients Market – Forecast (2022 - 2027)

Report Code: FBR 51697

Fish Oil Omega-3 Market

Report Code: FBR 26088

For more Food and Beverage Market reports, please click here